Document is current
Any future updates will be listed below
-
Authors
Hetlevik, Siri Opsahl https://orcid.org/0000-0001-9553-2322
Lilleby, Vibke
Pesonen, Maiju
Nordal, Ellen
Rygg, Marite
Austad, Cathrine
Jonsson, Maria Karolina
Bilstad, Maria
Høiberg, Hege Kilander
Sande, Nina Krafft
Flatø, Berit
Lillegraven, Siri
Haavardsholm, Espen A.
Ramanan, Athimalaipet V.
Molberg, Øyvind
Bøyesen, Pernille
Aga, Anna-Birgitte
-
Funding
Funding for this research was provided by:
Helse Sør-Øst RHF
Norske Kvinners Sanitetsforening
Norges Forskningsråd
Diakonhjemmet
- License Information
-
More Information
Article History
Received: 5 September 2025
Accepted: 2 February 2026
First Online: 17 February 2026
Declarations
:
: This study was approved by Norwegian Ethics Committee for Clinical trials on Medicinal Products and Medical Devices (REK KULMU), Regional Committees for Medical and Health Research Ethics South Norway (REK sør-øst) on the 28th of August 2024 (Clinical Trial Application EU CT 2024–512017–12–00). The study has approval of data handling and protection of data safety at all participating sites. All participants are given age-appropriate oral and written information about the study. The legal guardians are provided with oral and written information, and informed consent is signed before enrollment in the study. The MOVE-JIA study will be conducted according to the Declaration of Helsinki.
: Not applicable.
: The authors declare that they have no competing interests.
